1) To review the concepts behind development of anatomic imaging biomarkers. 2) To learn the strengths and weaknesses of RECIST and other anatomic imaging biomarkers. 3) New criteria for evaluation of gastrointestinal tumor response assessment.
Improvements in imaging technology and therapeutic options for the management of gastrointestinal tumors have revolutionized the way tumor response to therapy is assessed. Cytotoxic therapies result in tumor shrinkage and their efficacy is commonly assessed by evaluating tumor size based on strict guidelines such as the Response Evaluation Criteria in Solid Tumors (RECIST). This review will familiarize radiologists with the steps that have led to the development and modifications of the RECIST. New cytostatic and locoregional therapies may not change tumor size and have exposed many weaknesses of the RECIST. As a result, tumor and therapy specific response assessment criteria have been developed. These new criteria, including Choi, EASL, mRECIST and irRC will also be discussed.
Yaghmai, V,
RECIST and Other Criteria. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL.
http://archive.rsna.org/2014/13010451.html
